BMS sues over generic of blockbuster leukaemia treatment
04-10-2021
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
06-09-2021
nitpicker / Shutterstock.com
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kite Pharmaceuticals, Juno Therapeutics, Bristol Meyers Squibb, Gilead Sciences
